The long-acting somatostatin agonist Lanreotide (INN) was initially developed for the management of acromegaly, for which it has been approved in many countries. Consecutive studies showed that lanreotide alleviates symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome, and can serve as an alternative to octreotide in this field. Interestingly, lanreotide also shows activity against non-endocrine tumors, and, along with other somatostatin analogs, is being studied as a possible general anti-tumor agent.

Its anti-cancer activities turn lanreotide into a promising drug candidate and leave much room for the development of new indications and optimization of formulations. The peptide drug is usually administered as prolonged-release formulation.


Bachem, the world’s leading manufacturer of peptide active pharmaceutical ingredients, is your reliable source for lanreotide and other somatostatin agonists.

**Lanreotide**

H-9055-GMP

Sequence: H-D-2-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH₂ (Disulfide bond)

CAS-Number: 108736-35-2 (net), 127984-74-1 (acetate)

Molecular Formula: C₅₄H₆₉N₁₁O₁₀S₂

Molecular Weight 1096.34 g/mol

**Bachem is your trusted partner through all phases of drug development**

**Preclinical phase**
- Material for research purposes (non-GMP and GMP)
- Already available

**Clinical phases**
- Synthesis of the required GMP material including documentation CMC phase I-III, DMF
- Development and validation of analytical methods

**Market supply**
- Large-scale production for product launch
- Stability studies
- Commitment to our partners and projects
Generic APIs from Bachem

✓ Quality
  • GMP and non-GMP quality
  • Broad range of impurities & related products
  • State of the art analytical capabilities
  • ISO 13485 certified manufacturing site in St. Helens, UK

✓ Capacity
  • Production sites in the USA and Europe
  • Largest production facilities in the market
  • Up-to-date technology

✓ Support
  • Highly qualified technical support team
  • Documentation
  • Confidentiality
  • Industry leader and pioneering partner

The Swiss based Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides. As a full service provider, Bachem offers products for clinical development and commercial applications as well as a comprehensive catalog and exclusive custom synthesis. With 50 years of experience and subsidiaries in Switzerland, the United States, the United Kingdom and Japan, Bachem is the partner of choice for the biotech and pharma industry worldwide.

Bachem. Leading Partner in Tides